Abstract
Experimental studies have shown that sildenafil, a phosphodiesterase type 5 inhibitor, may have significant cardioprotective effects if used in low doses [[1, 2]].
Highlights
Experimental studies have shown that sildenafil, a phosphodiesterase type 5 inhibitor, may have significant cardioprotective effects if used in low doses [1,2]
The AUC10-60 min of mean arterial pressure values (MAP) plot was significantly lower in the control group, and both treatments produced significant increases in
Noradrenaline added to the sildenafil infusion was found to generate better values in the cardiovascular parameters (p < 0.01)
Summary
Experimental studies have shown that sildenafil, a phosphodiesterase type 5 inhibitor, may have significant cardioprotective effects if used in low doses [1,2]. Results Verapamil infusion produced decreases in the mean arterial pressure values (MAP).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have